Floatz logo

Clsp-5282

Pancreatic Carcinoma

Clasp Therapeutics, Inc.Phase 1Active
CC
41/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
81/ 100

Competitive context

103 Active assets in the Pancreatic Carcinoma cohort.

Asset / SponsorPhaseRating
Irinotecan
OHSU Knight Cancer Institute
Phase 2/3BBB
FLUOROURACILUM
Northwestern University
Phase 2/3BBB
Eloxatin
OHSU Knight Cancer Institute
Phase 2/3BBB
Gdc-0449
OHSU Knight Cancer Institute
Phase 2BB
Capecitabine
Zhejiang University
Phase 2BB

View all 50 →

Same molecule, other indications

Clsp-5282 is also rated in:

non-small cell lung carcinomaDormant
C
Indicative ·
37 / 100
View asset →
cancerDormant
C
Indicative ·
36 / 100
View asset →
colorectal cancerDormant
C
Indicative ·
36 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →